Want to see AHCO full AI Analyst Report?
AHCO Stock Chart & Stats
$10.76
$0.29(2.77%)
At close: 4:00 PM EDT
$10.76
$0.29(2.77%)
Day’s Range― - ―
52-Week Range$8.51 - $13.43
Previous Close$10.7
Volume821.52K
Average Volume (3M)1.41M
Market Cap
$1.53B
Enterprise Value$3.58K
Total Cash (Recent Filing)$47.96M
Total Debt (Recent Filing)$2.00B
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Aug 04, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding136,054,150
10 Day Avg. Volume1,077,853
30 Day Avg. Volume1,411,350
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.89
Price to Sales (P/S)0.41
P/FCF Ratio6.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.60Price Target Upside35.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.88
Revenue Forecast (FY)$3.49B
Bulls Say, Bears Say
Bulls Say
Recurring Resupply RevenueAdaptHealth’s core sleep and respiratory businesses generate recurring resupply revenue from implanted patient bases (masks, tubing, filters). That durable revenue mix supports predictable cash flow, higher lifetime customer value, and a defensible revenue floor versus one‑time device sales.
Large Capitated Contract ScaleThe 15M‑member capitated transition materially increases contracted recurring revenue and scale. Capitation shifts revenue toward predictable per‑member payments, aligns incentives, and can raise margins as utilization stabilizes, offering a structural boost to long‑term revenue quality and retention.
Consistent OCF And RefinancingConsistent operating cash flow plus the April $1.1B refinancing (TLA, delayed draw, revolver) lengthens maturities and lowers funding costs. That combination improves liquidity and gives time to execute deleveraging, fund capex for growth, and absorb transition costs without forcing asset sales.
Bears Say
Elevated LeverageLeverage near 3.0x leaves limited financial flexibility and raises interest/service risk if cash flow weakens. Even with refinancing and a deleveraging target, sustained free cash flow and margin recovery are required to reach 2.5x; adverse reimbursement or slower ramp could delay deleveraging.
Profitability VolatilityThe company’s profitability has been inconsistent, with net losses and compressed margins in recent periods. Below‑the‑line pressures and a weaker gross margin reduce earnings resilience; sustained margin improvement is necessary for durable EPS recovery and to convert strong OCF into equity returns.
Transition Capex & Cash StrainLarge upfront CapEx and transitional labor to support capitated rollouts compressed near‑term free cash flow and margins. If ramp or conversion takes longer than planned, recurring benefits may be delayed while balance sheet and liquidity bear continued cash consumption, slowing deleveraging progress.
AdaptHealth News
AHCO FAQ
What was AdaptHealth’s price range in the past 12 months?
AdaptHealth lowest stock price was $8.51 and its highest was $13.43 in the past 12 months.
What is AdaptHealth’s market cap?
AdaptHealth’s market cap is $1.53B.
When is AdaptHealth’s upcoming earnings report date?
AdaptHealth’s upcoming earnings report date is Aug 04, 2026 which is in 5 days.
How were AdaptHealth’s earnings last quarter?
AdaptHealth released its earnings results on May 05, 2026. The company reported -$0.056 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.068.
Is AdaptHealth overvalued?
According to Wall Street analysts AdaptHealth’s price is currently Undervalued.
Does AdaptHealth pay dividends?
AdaptHealth does not currently pay dividends.
What is AdaptHealth’s EPS estimate?
AdaptHealth’s EPS estimate is 0.17.
How many shares outstanding does AdaptHealth have?
AdaptHealth has 136,054,150 shares outstanding.
What happened to AdaptHealth’s price movement after its last earnings report?
AdaptHealth reported an EPS of -$0.056 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went down -9.893%.
Which hedge fund is a major shareholder of AdaptHealth?
Currently, no hedge funds are holding shares in AHCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AdaptHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.60 (35.69% Upside)
$14.60 (35.69% Upside)
Hedge Fund Trend
Decreased
By 121.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 12.5%
Last 30 Days ▲ 12.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.30%
Trailing 12-Months
Company Description
AdaptHealth
AdaptHealth Corp. (AHCO) is a home medical equipment (HME) provider in the U.S. healthcare sector. The company focuses on delivering, setting up, and supporting equipment and related supplies used in patients’ homes, with major product categories including sleep therapy (e.g., CPAP/BiPAP equipment and resupply), respiratory therapy, diabetes management supplies, and other durable medical equipment and home health solutions. AdaptHealth works with referral sources such as physicians and hospitals and serves patients whose care is reimbursed primarily through commercial insurers and government healthcare programs.
AHCO Company Deck
AHCO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a major strategic win — completion of a large capitated transition, robust organic revenue growth (9.1% y/y), strong segment performance (notably Sleep and Respiratory), important technology milestones, and a refinancing that improves financial flexibility. Near-term challenges include elevated transition-related labor costs ($12M), a Q1 adjusted EBITDA miss (~$7M), negative free cash flow in the quarter due to elevated CapEx ($121.2M), and a temporary increase in leverage to ~3.0x. Management expects labor costs and CapEx to normalize by mid-year, maintains full-year EBITDA and free cash flow guidance, and raised revenue guidance slightly. Overall, strategic progress and forward-looking actions appear to outweigh the near-term execution and cash impacts.View all AHCO earnings summariesAHCO Stock 12 Month Forecast
Average Price Target
$14.60
▲(35.69% Upside)
Technical Analysis
Ownership Overview
15.12% Insiders
23.32% Mutual Funds
6.23% Other Institutional Investors
31.24% Public Companies and
Individual Investors